Guy Sauvageau

Affiliation : Université de Montréal
Organization : Institut de recherche en immunologie et en cancérologie (IRIC)
E-mail :
Web site

About Guy Sauvageau

  • Principal Investigator, Molecular Genetics of Stem Cell Research Unit, IRIC
  • Professor, Department of Medicine, Faculty of Medicine, Université de Montréal
  • Associate Researcher, Department of Experimental Medicine, McGill University
  • Hematologist, Stem Cell Transplant Centre, Department of Hematology, Hôpital Maisonneuve-Rosemont
  • Scientific Advisor, Quebec Leukemia Cell Bank

Guy Sauvageau holds the Canada Research Chair in the Molecular Genetics of Stem Cells at the Institute for Research in Immunology and Cancer (IRIC) of Université de Montréal. He works as a hematologist at Hôpital Maisonneuve-Rosemont as part of a program on the transplant of hematopoietic stem cells. He was the founding scientific director of the Institute for Research in Immunology and Cancer of Université de Montréal (, cofounder of many initiatives, including the Centre de thérapie cellulaire de Montréal (, the Banque de leucémie du Québec ( and, more recently, a biotech company (


His work pertains to the molecular basis for self-renewal in hematopoietic, normal and leukemia stem cells. His lab is recognized for developing tests using primary cells adapted to high throughput screening of genes and small molecules involved in the expansion and differentiation of blood stem cells. In cooperation with several teams, including the IRIC team led by Dr. Marinier, he has identified the small UM729 molecule, optimized as UM171, which is currently undergoing clinical trials for cord blood stem transplants for leukemia. Working closely with Josée Hébert, Anne Marinier, Sébastien Lemieux and Ma’n Zawati, Dr. Sauvageau spearheads a large-scale project on acute myeloid leukemia (AML). The program, known as Leucegene (, focuses on developing diagnostic and prognostic tests for AML and, most recently on creating new targeted therapies. The characterization of the transcriptional and mutational profiles of AML subgroups included in the Leucegene cohort has led to many discoveries, such as the development and validation of a new AML prognostic test that predicts the resistance to current therapies and reassigns approximately 30 percent of patients. The program is now in its therapeutic phase with results being extremely promising.

Ongoing competitions